PANTS extension study: how best to use anti-TNF drugs in Crohn's disease

Lancet Gastroenterol Hepatol. 2024 Jun;9(6):489-491. doi: 10.1016/S2468-1253(24)00088-8. Epub 2024 Apr 16.

Authors

Gareth C Parkes¹, Charlotte R H Hedin²

Affiliations

¹ Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK.
² Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden; Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Centre for Digestive Health, Stockholm 17164, Sweden. Electronic address: charlotte.hedin@ki.se.

PMID: 38640938
DOI: 10.1016/S2468-1253(24)00088-8

No abstract available

MeSH terms

Adalimumab / adverse effects
Adalimumab / therapeutic use
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Crohn Disease* / drug therapy
Gastrointestinal Agents / adverse effects
Gastrointestinal Agents / therapeutic use
Humans
Infliximab* / adverse effects
Infliximab* / therapeutic use
Randomized Controlled Trials as Topic
Treatment Outcome
Tumor Necrosis Factor-alpha* / antagonists & inhibitors

Substances

Tumor Necrosis Factor-alpha
Infliximab
Adalimumab
Antibodies, Monoclonal, Humanized
Gastrointestinal Agents
Antibodies, Monoclonal